Brief: Viking Therapeutics Q1 EPS USD -1.37 Vs. IBES Estimate USD -1.01
29/04/2026 21:05
Apr 29 (Reuters) - Viking Therapeutics Q1 operating expenses USD 164.125 million. Q1 income from operations USD -164.125 million vs. IBES estimate USD -130 million Q1 net income USD -158.325 million vs. IBES estimate USD -113.8 million
Recent news on Viking Therapeutics
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry